These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 16779800

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.
    Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL.
    Cancer; 2010 May 01; 116(9):2132-9. PubMed ID: 20166215
    [Abstract] [Full Text] [Related]

  • 8. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
    Cabrespine A, Guy L, Khenifar E, Curé H, Fleury J, Penault-Llorca F, Kwiatkowski F, Barthomeuf C, Chollet P, Bay JO.
    Urology; 2006 Feb 01; 67(2):354-9. PubMed ID: 16442593
    [Abstract] [Full Text] [Related]

  • 11. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM.
    Cancer; 2006 Sep 01; 107(5):1093-100. PubMed ID: 16888761
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
    Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ.
    Cancer; 2003 Feb 01; 97(3):561-7. PubMed ID: 12548597
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
    Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, Wake K, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M.
    Eur Urol; 2007 May 01; 51(5):1252-8. PubMed ID: 17208356
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy.
    Romero S, Stanton G, DeFelice J, Schreiber F, Rago R, Fishman M.
    Urol Oncol; 2007 May 01; 25(4):284-90. PubMed ID: 17628293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.